The pharmaceutical industry is once again approaching a major patent cliff, with several blockbuster therapies set to lose exclusivity over the next few years. For many companies, these products have ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
